Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study

C. Barone, A. Cassano, A. Astone, E. Ricevuto, T. Fontana, M. R. Noviello, C. Garufi, F. Pacelli, A. Grieco

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3±7%); 9 patients had partial response (31±17%); 5 patients (17±14%) were considered stable (S) and 14 (48±18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.

Original languageEnglish
Pages (from-to)353-355
Number of pages3
JournalOncology
Volume48
Issue number5
Publication statusPublished - 1991

Fingerprint

Epirubicin
Etoposide
Cisplatin
Stomach Neoplasms
Fluorouracil
Drug Combinations
Stomach
Adenocarcinoma
Survival

Keywords

  • Chemotherapy
  • Cisplatin
  • Epirubicin
  • Etoposide
  • Gastric cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Barone, C., Cassano, A., Astone, A., Ricevuto, E., Fontana, T., Noviello, M. R., ... Grieco, A. (1991). Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. Oncology, 48(5), 353-355.

Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. / Barone, C.; Cassano, A.; Astone, A.; Ricevuto, E.; Fontana, T.; Noviello, M. R.; Garufi, C.; Pacelli, F.; Grieco, A.

In: Oncology, Vol. 48, No. 5, 1991, p. 353-355.

Research output: Contribution to journalArticle

Barone, C, Cassano, A, Astone, A, Ricevuto, E, Fontana, T, Noviello, MR, Garufi, C, Pacelli, F & Grieco, A 1991, 'Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study', Oncology, vol. 48, no. 5, pp. 353-355.
Barone C, Cassano A, Astone A, Ricevuto E, Fontana T, Noviello MR et al. Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. Oncology. 1991;48(5):353-355.
Barone, C. ; Cassano, A. ; Astone, A. ; Ricevuto, E. ; Fontana, T. ; Noviello, M. R. ; Garufi, C. ; Pacelli, F. ; Grieco, A. / Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study. In: Oncology. 1991 ; Vol. 48, No. 5. pp. 353-355.
@article{b6392d71e7934be088de8ceb0af81831,
title = "Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study",
abstract = "Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3±7{\%}); 9 patients had partial response (31±17{\%}); 5 patients (17±14{\%}) were considered stable (S) and 14 (48±18{\%}) were classified as progressive. The average survival time for the entire group was 11 months with 25{\%} of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.",
keywords = "Chemotherapy, Cisplatin, Epirubicin, Etoposide, Gastric cancer",
author = "C. Barone and A. Cassano and A. Astone and E. Ricevuto and T. Fontana and Noviello, {M. R.} and C. Garufi and F. Pacelli and A. Grieco",
year = "1991",
language = "English",
volume = "48",
pages = "353--355",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

TY - JOUR

T1 - Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study

AU - Barone, C.

AU - Cassano, A.

AU - Astone, A.

AU - Ricevuto, E.

AU - Fontana, T.

AU - Noviello, M. R.

AU - Garufi, C.

AU - Pacelli, F.

AU - Grieco, A.

PY - 1991

Y1 - 1991

N2 - Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3±7%); 9 patients had partial response (31±17%); 5 patients (17±14%) were considered stable (S) and 14 (48±18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.

AB - Cisplatin-based drug combinations are now currently investigated in an attempt to surpass the results obtainable by 5-FU alone or by 5-FU-containing regimens. We evaluated 29 patients with advanced and measurable gastric adenocarcinoma treated with etoposide, epirubicin and cisplatin. One patient had complete response (3±7%); 9 patients had partial response (31±17%); 5 patients (17±14%) were considered stable (S) and 14 (48±18%) were classified as progressive. The average survival time for the entire group was 11 months with 25% of the patients alive at 24 months. We feel that cisplatin-containing regimens are promising and deserve further investigations. To clearly explore the potential innovative role of these regimens randomized trials versus FAM or 5-FU alone are mandatory.

KW - Chemotherapy

KW - Cisplatin

KW - Epirubicin

KW - Etoposide

KW - Gastric cancer

UR - http://www.scopus.com/inward/record.url?scp=0025953890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025953890&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 353

EP - 355

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 5

ER -